SCHEMBL19002424

SCHEMBL19002424

CNCCc1nnc2n1CCC2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.45
MAPT P10636 1/20 0.43
KDM4E B2RXH2 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
LMNA P02545 5/20 0.42
CHRM2 P08172 1/20 0.41
HTR1A P08908 1/20 0.41
ADRA2A P08913 1/20 0.41
ADRA2B P18089 1/20 0.41
ADRA1D P25100 1/20 0.41
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
SLC6A4 P31645 1/20 0.41
ADRA1A P35348 1/20 0.41
DRD3 P35462 1/20 0.41
HTR2B P41595 1/20 0.41
TSHR P16473 2/20 0.40
GAA P10253 2/20 0.40
TP53 P04637 2/20 0.40
GFER P55789 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23222367 0.83 MAPT (0.42) POLBMAPTKDM4EL3MBTL1LMNA
SCHEMBL9965967 0.82 MAPT (0.52) POLBMAPTKDM4EL3MBTL1LMNA
SCHEMBL18997320 0.82 L3MBTL1 (0.41) POLBMAPTKDM4EL3MBTL1LMNA
SCHEMBL8367476 0.80 KDM4E (0.47) POLBMAPTKDM4EL3MBTL1LMNA
SCHEMBL14048238 0.76 POLB (0.47) POLBMAPTKDM4EL3MBTL1LMNA
SCHEMBL13870117 0.75 L3MBTL1 (0.52) POLBMAPTKDM4EL3MBTL1LMNA
SCHEMBL9963371 0.72 MAPT (0.50) POLBMAPTKDM4EL3MBTL1LMNA
SCHEMBL14759259 0.72 POLB (0.47) POLBMAPTKDM4EL3MBTL1LMNA
SCHEMBL25319495 0.72 POLB (0.47) POLBMAPTKDM4EL3MBTL1LMNA
SCHEMBL24174155 0.71 POLB (0.44) POLBMAPTKDM4EL3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3394056-B1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE SHY Therapeutics LLC (US) 2021-04-14 EP disclosed
WO-2017112777-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE SHY Therapeutics LLC (US) 2017-06-29 WO disclosed
US-20170174699-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE SHY Therapeutics LLC 2017-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170174699-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE MAPK6, MAP3K6, MAPK4 POLB 1589/4885MAPT 2731/4885KDM4E 3392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.